CD274 and cancer: From the discovery of PD-1/PD-L1 and CTLA4 to the commercialization of immune checkpoint inhibitors and, more recently, optimizing chimeric antigen receptor T-cell therapies, the versatility of T cells in tumors offers a unique diving board for the development of cancer immunotherapies (101–104).